as 04-01-2025 3:38pm EST
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | MIAMI |
Market Cap: | 27.6M | IPO Year: | 2021 |
Target Price: | $8.67 | AVG Volume (30 days): | 201.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.62 | EPS Growth: | N/A |
52 Week Low/High: | $0.77 - $6.40 | Next Earning Date: | 05-13-2025 |
Revenue: | $2,392,000 | Revenue Growth: | 237.38% |
Revenue Growth (this year): | 26.05% | Revenue Growth (next year): | 12.27% |
LGVN Breaking Stock News: Dive into LGVN Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
GlobeNewswire
13 days ago
Zacks Small Cap Research
13 days ago
GlobeNewswire
22 days ago
GlobeNewswire
a month ago
Zacks Small Cap Research
a month ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
The information presented on this page, "LGVN Longeveron Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.